Basket Study for Oligo-metastatic Breast Cancer
NCT05982678
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
72
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Breast Cancer
Interventions
DRUG:
Trastuzumab deruxtecan
Sponsor
The Netherlands Cancer Institute
Collaborators
[object Object]
[object Object]